Dolasetron

Diagram of the molecular structure of Dolasetron
Brand name: Anzemet®
IUPAC: (3R)-10-oxo-8-azatricyclo[5.3.1.03,8]undec-5-yl 1H-indole-3-carboxylate
FDA approval: Yes
Usage:

Dolasetron mesylate (Anzemet®) is used to the prevent nausea and vomiting associated with cytotoxic effects of chemotherapy. Dolasetron is administered in pill form.1 In December 2010, the U.S. FDA blocked the use of the injected (intravenous) form of the drug for the prevention of nausea due to chemotherapy.2

  • 1Anzemet.. Prescribing Information. Aventis Pharmaceuticals. September, 2016. [http://www.anzemet.com]
  • 2https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-use-anzemet-dolasetron-mesylate
Mechanism:

Dolasteron works by blocking the reception of serotonin at 5-HT3 receptors. When these receptors are bound by serotonin, they induce nausea and the vomiting reflex.

The structure below shows the 3D conformer Dolasetron.

 

Side effects:

The most common side effects associated with the use of Anzemet® during chemotherapy regimens are headache, fatigue and diarrhea. The intravenous version of the drug was associated with abnormal heart rhythms.